{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T04:18:17Z","timestamp":1776745097737,"version":"3.51.2"},"reference-count":50,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2019,9,26]],"date-time":"2019-09-26T00:00:00Z","timestamp":1569456000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP18K15824"],"award-info":[{"award-number":["JP18K15824"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Hyperglycemia and hyperinsulinemia activate the proliferative potential of hepatic stellate cells (HSCs) and promote hepatic fibrosis. Dipeptidyl peptidase-4 (DPP-4) inhibitors, antidiabetic agents, reportedly inhibit the HSC proliferation. Additionally, Takeda G protein-coupled receptor 5 (TGR5) agonists induce the systemic release of glucagon-like peptides from intestinal L cells, which maintains glycemic homeostasis. This study assessed the combined effect of TGR5 agonist and DPP-4 inhibitor on diabetes-based liver fibrosis development. Male diabetic rats received intraperitoneal injection of porcine serum (PS) to induce liver fibrosis, and they were orally administered the following agents: oleanolic acid (OA) as a TGR5 agonist, anagliptin (ANA) as a DPP-4 inhibitor, and a combination of both agents. Treatment with OA or ANA significantly improved glycemic status and attenuated intrahepatic steatosis and lipid peroxidation in diabetic rats. PS-induced liver fibrosis development was also drastically suppressed by treatment with either agent, and the combination of both reciprocally enhanced the antifibrotic effect. Fecal microbiome demonstrated that both agents inhibited the increase in the Firmicutes\/Bacteroidetes ratio, an indicator of dysbiosis related to metabolic syndromes. Furthermore, ANA directly inhibited in vitro HSC proliferative and profibrogenic activities. Collectively, TGR5 agonist and DPP-4 inhibitor appears to be a novel strategy against liver fibrosis under diabetic conditions.<\/jats:p>","DOI":"10.3390\/cells8101153","type":"journal-article","created":{"date-parts":[[2019,9,27]],"date-time":"2019-09-27T03:03:15Z","timestamp":1569553395000},"page":"1153","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["TGR5 Activation Modulates an Inhibitory Effect on Liver Fibrosis Development Mediated by Anagliptin in Diabetic Rats"],"prefix":"10.3390","volume":"8","author":[{"given":"Daisuke","family":"Kaya","sequence":"first","affiliation":[{"name":"Third Department of Internal Medicine, Nara Medical University, Kashihara, Nara 634-8521, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kosuke","family":"Kaji","sequence":"additional","affiliation":[{"name":"Third Department of Internal Medicine, Nara Medical University, Kashihara, Nara 634-8521, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Tsuji","sequence":"additional","affiliation":[{"name":"Third Department of Internal Medicine, Nara Medical University, Kashihara, Nara 634-8521, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoko","family":"Yamashita","sequence":"additional","affiliation":[{"name":"Sanwa Kagaku Kenkyusho, Co., Ltd., Nagoya, Aichi 461-8631, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koh","family":"Kitagawa","sequence":"additional","affiliation":[{"name":"Third Department of Internal Medicine, Nara Medical University, Kashihara, Nara 634-8521, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Ozutsumi","sequence":"additional","affiliation":[{"name":"Third Department of Internal Medicine, Nara Medical University, Kashihara, Nara 634-8521, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukihisa","family":"Fujinaga","sequence":"additional","affiliation":[{"name":"Third Department of Internal Medicine, Nara Medical University, Kashihara, Nara 634-8521, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroaki","family":"Takaya","sequence":"additional","affiliation":[{"name":"Third Department of Internal Medicine, Nara Medical University, Kashihara, Nara 634-8521, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4361-0592","authenticated-orcid":false,"given":"Hideto","family":"Kawaratani","sequence":"additional","affiliation":[{"name":"Third Department of Internal Medicine, Nara Medical University, Kashihara, Nara 634-8521, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kei","family":"Moriya","sequence":"additional","affiliation":[{"name":"Third Department of Internal Medicine, Nara Medical University, Kashihara, Nara 634-8521, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadashi","family":"Namisaki","sequence":"additional","affiliation":[{"name":"Third Department of Internal Medicine, Nara Medical University, Kashihara, Nara 634-8521, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6675-0475","authenticated-orcid":false,"given":"Takemi","family":"Akahane","sequence":"additional","affiliation":[{"name":"Third Department of Internal Medicine, Nara Medical University, Kashihara, Nara 634-8521, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitoshi","family":"Yoshiji","sequence":"additional","affiliation":[{"name":"Third Department of Internal Medicine, Nara Medical University, Kashihara, Nara 634-8521, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2019,9,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1172\/JCI24282","article-title":"Liver fibrosis","volume":"115","author":"Bataller","year":"2005","journal-title":"J. Clin. Invest."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1055\/s-2007-991517","article-title":"Hepatic fibrogenesis","volume":"27","author":"Guo","year":"2007","journal-title":"Semin Liver Dis."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1053\/j.gastro.2008.03.003","article-title":"Mechanisms of hepatic fibrogenesis","volume":"134","author":"Friedman","year":"2008","journal-title":"Gastroenterology."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1002\/hep.510290632","article-title":"Insulin and insulin-like growth factor-1 stimulate proliferation and type I collagen accumulation by human hepatic stellate cells: Differential effects on signal transduction pathways","volume":"29","author":"Ridolfi","year":"1999","journal-title":"Hepatology"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1111\/j.1478-3231.2005.01130.x","article-title":"High glucose stimulates hepatic stellate cells to proliferate and to produce collagen through free radical production and activation of mitogen-activated protein kinase","volume":"25","author":"Sugimoto","year":"2005","journal-title":"Liver Int."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1002\/hep.1840190312","article-title":"Pathogenesis of glucose intolerance and diabetes mellitus in cirrhosis","volume":"19","author":"Petrides","year":"1994","journal-title":"Hepatology"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S0168-8278(01)00143-X","article-title":"Risk factors for diabetes mellitus and early insulin resistance in chronic hepatitis C","volume":"35","author":"Petit","year":"2001","journal-title":"J. Hepatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1002\/hep.20920","article-title":"Insulin resistance: A metabolic pathway to chronic liver disease","volume":"42","author":"Bugianesi","year":"2005","journal-title":"Hepatology"},{"key":"ref_9","first-page":"801","article-title":"Impact of insulin resistance on the progression of chronic liver diseases","volume":"22","author":"Kaji","year":"2008","journal-title":"Int. J. Mol. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1053\/j.gastro.2015.04.043","article-title":"Liver Fibrosis, but No Other Histologic Features, Is Associated with Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease","volume":"149","author":"Angulo","year":"2015","journal-title":"Gastroenterology"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s00535-013-0783-4","article-title":"Dipeptidyl peptidase-4 inhibitor attenuates hepatic fibrosis via suppression of activated hepatic stellate cell in rats","volume":"49","author":"Kaji","year":"2014","journal-title":"J. Gastroenterol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.jhep.2016.04.021","article-title":"Sitagliptin vs. placebo for non-alcoholic fatty liver disease: A randomized controlled trial","volume":"65","author":"Cui","year":"2016","journal-title":"J. Hepatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"141","DOI":"10.3748\/wjg.v23.i1.141","article-title":"Sitagliptin in patients with non-alcoholic steatohepatitis: A randomized, placebo-controlled trial","volume":"23","author":"Joy","year":"2017","journal-title":"World J. Gastroenterol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.dld.2013.10.021","article-title":"The bile acid TGR5 membrane receptor: From basic research to clinical application","volume":"46","author":"Duboc","year":"2014","journal-title":"Dig. Liver Dis."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1002\/hep.24525","article-title":"The G-protein-coupled bile acid receptor, Gpbar1 (TGR5), negatively regulates hepatic inflammatory response through antagonizing nuclear factor kappa light-chain enhancer of activated B cells (NF-kappaB) in mice","volume":"54","author":"Wang","year":"2011","journal-title":"Hepatology"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1136\/gutjnl-2015-309458","article-title":"TGR5 is essential for bile acid-dependent cholangiocyte proliferation in vivo and in vitro","volume":"65","author":"Reich","year":"2016","journal-title":"Gut"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e12462","DOI":"10.1111\/1755-5922.12462","article-title":"TGR5 activation induces cytoprotective changes in the heart and improves myocardial adaptability to physiologic, inotropic, and pressure-induced stress in mice","volume":"36","author":"Eblimit","year":"2018","journal-title":"Cardiovasc. Ther."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/S2213-8587(16)30155-3","article-title":"Clinical relevance of the bile acid receptor TGR5 in metabolism","volume":"5","author":"Scheltema","year":"2017","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1111\/bph.12158","article-title":"Systemic bile acid sensing by G protein-coupled bile acid receptor 1 (GPBAR1) promotes PYY and GLP-1 release","volume":"169","author":"Ullmer","year":"2013","journal-title":"Br. J. Pharmacol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1038\/nrendo.2012.140","article-title":"GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus","volume":"8","author":"Meier","year":"2012","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"d7771","DOI":"10.1136\/bmj.d7771","article-title":"Effects of glucagon-like peptide-1 receptor agonists on weight loss: Systematic review and meta-analyses of randomised controlled trials","volume":"344","author":"Vilsboll","year":"2012","journal-title":"BMJ"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/hep.21006","article-title":"Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob\/ob mice","volume":"43","author":"Ding","year":"2006","journal-title":"Hepatology"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"G225","DOI":"10.1152\/ajpgi.00274.2011","article-title":"Glp-1 analog, liraglutide, ameliorates hepatic steatosis and cardiac hypertrophy in C57BL\/6J mice fed a Western diet","volume":"302","author":"Mells","year":"2012","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"G762","DOI":"10.1152\/ajpgi.00476.2011","article-title":"Glucagon-like peptide-1 receptor agonism improves metabolic, biochemical, and histopathological indices of nonalcoholic steatohepatitis in mice","volume":"302","author":"Trevaskis","year":"2012","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","article-title":"Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): A multicentre, double-blind, randomised, placebo-controlled phase 2 study","volume":"387","author":"Armstrong","year":"2016","journal-title":"Lancet"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.cmet.2009.08.001","article-title":"TGR5-mediated bile acid sensing controls glucose homeostasis","volume":"10","author":"Thomas","year":"2009","journal-title":"Cell Metab."},{"key":"ref_27","first-page":"773","article-title":"Extracellular matrix components induce endocrine differentiation in vitro in NCI-H716 cells","volume":"142","author":"Dinjens","year":"1993","journal-title":"Am. J. Pathol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software \u2019EZR\u2019 for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1111\/j.1476-5381.2011.01561.x","article-title":"Molecular mechanisms underlying bile acid-stimulated glucagon-like peptide-1 secretion","volume":"165","author":"Parker","year":"2012","journal-title":"Br. J. Pharmacol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"26488","DOI":"10.1074\/jbc.270.44.26488","article-title":"Differential processing of proglucagon by the subtilisin-like prohormone convertases PC2 and PC3 to generate either glucagon or glucagon-like peptide","volume":"270","author":"Rouille","year":"1995","journal-title":"J. Biol. Chem."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S0168-8278(01)00142-8","article-title":"Oxidative stress-related molecules and liver fibrosis","volume":"35","author":"Parola","year":"2001","journal-title":"J. Hepatol."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Zhang, Q., Xiao, X., Li, M., Yu, M., Ping, F., Zheng, J., Wang, T., and Wang, X. (2017). Vildagliptin increases butyrate-producing bacteria in the gut of diabetic rats. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0184735"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1177\/0148607116661838","article-title":"Preserved Gut Microbial Diversity Accompanies Upregulation of TGR5 and Hepatobiliary Transporters in Bile Acid-Treated Animals Receiving Parenteral Nutrition","volume":"41","author":"Jain","year":"2017","journal-title":"JPEN J. Parenter. Enteral Nutr."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1038\/nature05414","article-title":"An obesity-associated gut microbiome with increased capacity for energy harvest","volume":"444","author":"Turnbaugh","year":"2006","journal-title":"Nature"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1053\/j.gastro.2009.08.042","article-title":"High-fat diet determines the composition of the murine gut microbiome independently of obesity","volume":"137","author":"Hildebrandt","year":"2009","journal-title":"Gastroenterology"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1136\/gut.2010.215665","article-title":"Composition and energy harvesting capacity of the gut microbiota: Relationship to diet, obesity and time in mouse models","volume":"59","author":"Murphy","year":"2010","journal-title":"Gut"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.diabres.2014.04.028","article-title":"Sitagliptin attenuates methionine\/choline-deficient diet-induced steatohepatitis","volume":"105","author":"Jung","year":"2014","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"6895","DOI":"10.3892\/mmr.2015.4329","article-title":"Therapeutic effects of the dipeptidyl peptidase-IV inhibitor, sitagliptin, on non-alcoholic steatohepatitis in FLS-ob\/ob male mice","volume":"12","author":"Onoyama","year":"2015","journal-title":"Mol. Med. Rep."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1111\/hepr.12860","article-title":"Combined treatment with dipeptidyl peptidase-4 inhibitor (sitagliptin) and angiotensin-II type 1 receptor blocker (losartan) suppresses progression in a non-diabetic rat model of steatohepatitis","volume":"47","author":"Okura","year":"2017","journal-title":"Hepatol. Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1034\/j.1600-0676.2001.210101.x","article-title":"Involvement of reactive oxygen species and nitric oxide radicals in activation and proliferation of rat hepatic stellate cells","volume":"21","author":"Saccomanno","year":"2001","journal-title":"Liver"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1002\/hep.510290631","article-title":"Fibroblast activation protein: A cell surface dipeptidyl peptidase and gelatinase expressed by stellate cells at the tissue remodelling interface in human cirrhosis","volume":"29","author":"Levy","year":"1999","journal-title":"Hepatology"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/icb.2016.116","article-title":"The pro-fibrotic role of dipeptidyl peptidase 4 in carbon tetrachloride-induced experimental liver injury","volume":"95","author":"Wang","year":"2017","journal-title":"Immunol. Cell Biol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.bbrc.2019.02.065","article-title":"Alogliptin alleviates liver fibrosis via suppression of activated hepatic stellate cell","volume":"511","author":"Zhang","year":"2019","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Bi, S., Chu, F., Wang, M., Li, B., Mao, P., Zhang, H., Wang, P., Guo, W., Xu, L., and Ren, L. (2016). Ligustrazine-Oleanolic Acid Glycine Derivative, G-TOA, Selectively Inhibited the Proliferation and Induced Apoptosis of Activated HSC-T6 Cells. Molecules, 21.","DOI":"10.3390\/molecules21111599"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"10067","DOI":"10.1002\/jcb.27343","article-title":"Identification of therapeutic effect of glucagon-like peptide 1 in the treatment of STZ-induced diabetes mellitus in rats by restoring the balance of intestinal flora","volume":"119","author":"Yuan","year":"2018","journal-title":"J. Cell Biochem."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.3389\/fmicb.2017.02271","article-title":"Flos Lonicera Combined with Metformin Ameliorates Hepatosteatosis and Glucose Intolerance in Association with Gut Microbiota Modulation","volume":"8","author":"Shin","year":"2017","journal-title":"Front. Microbiol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/j.bcp.2008.12.028","article-title":"Oleanolic acid activates Nrf2 and protects from acetaminophen hepatotoxicity via Nrf2-dependent and Nrf2-independent processes","volume":"77","author":"Reisman","year":"2009","journal-title":"Biochem Pharmacol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.taap.2013.08.003","article-title":"Oleanolic acid alters bile acid metabolism and produces cholestatic liver injury in mice","volume":"272","author":"Liu","year":"2013","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"3060","DOI":"10.3390\/molecules18033060","article-title":"Repeated oral administration of oleanolic acid produces cholestatic liver injury in mice","volume":"18","author":"Lu","year":"2013","journal-title":"Molecules"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1002\/hep.510230423","article-title":"Contribution of immune response to the hepatic fibrosis induced by porcine serum","volume":"23","author":"Bhunchet","year":"1996","journal-title":"Hepatology"}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/8\/10\/1153\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:24:41Z","timestamp":1760189081000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/8\/10\/1153"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,26]]},"references-count":50,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2019,10]]}},"alternative-id":["cells8101153"],"URL":"https:\/\/doi.org\/10.3390\/cells8101153","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,26]]}}}